Prot #AG-221-AML-004: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogen

Project: Research project

Project Details

StatusActive
Effective start/end date3/30/163/30/22

Funding

  • PPD Development (Prot #AG-221-AML-004)
  • Celgene Corporation (Prot #AG-221-AML-004)